Blog

Quovo Raises $10 Million in Series B Funding

NEW YORK, April 26, 2017 /PRNewswire/ — Quovo, a data platform providing insights and connectivity for financial accounts, today announced it has raised $10 million in Series B funding. F-Prime Capital and Napier Park Financial Partners co-led the round and were joined by existing investors, FinTech Collective and Long Light Capital. Quovo will use the funds to accelerate the growth of its suite of data analytics offerings, which include the company’s recently launched bank authentication API and Quovo Connect module.

By providing efficient access to financial account aggregation and analytics via APIs and front-end dashboards, Quovo has played a key role in driving the ongoing digital transformation in wealth management. Demand for high-quality financial account data is rapidly growing as the broader financial services industry turns to data to optimize their client relationships and drive valuable insights. Leading this trend, Quovo has expanded across multiple financial services verticals, offering solutions for banking, lending, insurance, and more.

This expansion has most recently led to the launch and growth of Quovo’s Bank Authentication API and the launch of Quovo Connect, an easy-to-use module that offers an elegant user experience for adding financial accounts from thousands of institutions. The new Bank API and Quovo Connect are both easily embedded into any website or mobile app with just a few lines of code.

Read More

Acacia Pharma announces positive results from its fourth and final pivotal trial of Baremsis™ for the rescue treatment of PONV

Cambridge, UK – Acacia Pharma Group Ltd (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces positive results from its fourth and final pivotal Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) for the rescue treatment of patients who develop post-operative nausea & vomiting (PONV), despite having received prior antiemetic prophylaxis.

Dr Julian Gilbert, Acacia Pharma’s CEO commented: “We are delighted with these results demonstrating that BAREMSIS is safe and effective at rescuing patients who suffer PONV despite having received prior prophylaxis with standard anti-emetics. No other anti-emetic has a specific label for treating this significant unmet need and we intend to position BAREMSIS as the drug of choice for treating the 30-40% of surgical patients who suffer PONV despite prior prophylaxis, as well as for combination prophylaxis in high-risk patients.”

Acacia Pharma has now completed four pivotal Phase 3 studies of BAREMSIS successfully, all meeting their primary endpoint, and these will form the basis of the efficacy and safety package which the Company aims to submit to the US FDA as part of its New Drug Application (NDA) in 1H 2017. The Company will seek a broad and unique approval for BAREMSIS for the rescue treatment and prophylaxis of PONV, alone and in combination.

Read More

WelbeHealth Announces $15 Million of Funding from F-Prime Capital and .406 Ventures

WelbeHealth, a healthcare services company delivering coordinated and value-based care to medically frail seniors, has raised $15 million in Series A funding led by F-Prime Capital and .406 Ventures. Jon Lim, a partner of F-Prime Capital, and Liam Donohue, managing partner of .406 Ventures, will join WelbeHealth’s board in conjunction with the financing. WelbeHealth will use the financing to develop its initial market and roll out new initiatives to improve the quality of care for seniors.

“We founded this company around the mission of serving our most vulnerable seniors with greater quality and compassion in a value-based model,” said Si France, MD, co-founder and CEO of WelbeHealth. “So we were very deliberate in selecting successful investors who have experience partnering with entrepreneurs to build truly mission-driven healthcare services companies.” F-Prime Capital and .406 Ventures have been early investors in leading healthcare startups such as Iora Health, US HealthVest, Quartet Health, AbleTo, Health Dialog, and axialHealthcare.

Read More

PatientPing partners with Hackensack Meridian Health to bring care coordination to health care providers in New Jersey

PatientPing, a health technology company that connects providers to seamlessly coordinate patient care, announced today that it has partnered with Hackensack Meridian Health in New Jersey, marking PatientPing’s seventh state where it’s achieving higher quality care through better patient care coordination. This partnership with New Jersey’s most integrated and comprehensive health care system will ultimately encompass full data sharing across all of Hackensack Meridian Health’s 13 hospitals, meaning that providers in the state will be able to see where patients are admitted, discharged or transferred to/from a Hackensack Meridian Health Hospital.

“Hackensack Meridian Health is dedicated to providing well-orchestrated, quality care to our patients,” said Patrick Young, president of Population Health, Hackensack Meridian Health. “Our relationship with PatientPing underscores this commitment by offering a simple yet powerful solution that enables the delivery of coordinated care across our continuum from our hospitals to our outpatient and post-acute facilities.”

PatientPing aims to advance medical information transparency between health care providers by applying its technology to improve patient care. Upon joining PatientPing, providers receive “Pings,” or real-time notifications, whenever their patients receive care at a wide range of facilities in NJ and beyond. At the facility where patients are getting care, providers receive care instructions that include contact information for others on the patient’s care team as well as patient visit histories. By sharing this information in real time, providers are able to apply timely interventions, avoid unnecessary readmissions, and ensure safer care transitions for their patients.

Read More

US HealthVest opens second Atlanta hospital, serves unmet need for specialized psychiatric care

US HealthVest announced the opening of Ridgeview Institute – Monroe, a 70-bed psychiatric hospital that provides a full continuum of inpatient and outpatient psychiatric care to patients of all ages.

“We are excited to bring these vital services to the community,” said Richard Kresch, M.D., President and CEO of US HealthVest. “With two hospitals in the Atlanta region, we are well positioned to treat the increasing and unmet need for specialized psychiatric care in the growing metro area.”

Located at 709 Breedlove Drive in Monroe, the hospital provides behavioral health and addiction treatment services for children, adolescents, adults and senior adults. Comprehensive services include free 24/7 assessments, inpatient and intensive outpatient care. A full range of specialized programs such as a Women’s Program and a Geriatric Program will also be provided.

Read More

Surface Oncology Welcomes Industry Leader Daniel S. Lynch as Chairman of Board of Directors

Surface Oncology, an immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of industry leader Daniel S. Lynch, as Executive Chairman of the company’s Board of Directors. Mr. Lynch’s appointment brings additional industry leadership experience to the Board as the company advances its pipeline of next-generation immunotherapies towards the clinic. Mr. Lynch will succeed Dr. David Grayzel, a co-founder of Surface Oncology who has served as Chairman since the company was formed. Dr. Grayzel will continue as a member of the Board.

 

With over 25 years of industry experience, Mr. Lynch has advised and served as Chairman or Board member for a number of top tier biotechnology companies. He currently serves on the Boards of several biotech companies, including Bluebird Bio, RaNA Therapeutics, and BluePrint Medicines. He previously served on the Boards of a range of additional companies, including Nimbus Therapeutics, Avila Therapeutics, and Stromedix. Over the course of his career, Mr. Lynch has successfully helped to guide multiple biotech companies through their entry into the public markets.

Read More

Even Financial Milestone: Surpasses $1.5 Billion in Loan Requests & Increases Online Loan Originations by 205%

Earlier this week, fintech firm Even Financial announced it increased loan originations by 205% quarter over quarter since the beginning of 2016 and surpassed $1.5 billion in loan requests. The company has experienced solid growth since it was founded in 2014.

Even Financial is aiming to become an important supply channel for online lenders in search of borrowers. The company claims to be the first and only dedicated supply-side platform for both online financial products and services. Even has established a set of well-known online finance partners, such as Prosper, Ascend, and Upstart, providing an integrated real-time API for search, comparison, and loan recommendations.

Following Even Financial’s latest milestone news, CEO Phill Rosen shared details about the platform’s development and the P2P industry with Crowdfund Insider.

Read More

Surface Oncology Appoints Robert Ross, MD as Chief Medical Officer

Surface Oncology, an immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Robert W. Ross, MD as its Chief Medical Officer. Dr. Ross will be responsible for advancing Surface Oncology’s development programs, including SRF231, a fully human CD47 antibody, into and through the clinic. Dr. Ross joins Surface from bluebird bio, where he was most recently head of the Oncology franchise and Senior Vice President of Clinical Development and pharmacovigilance.

“Immune therapy is the future of oncology treatment. In the last five years, with the introduction of immune system modulation, the lives of patients have been fundamentally changed, but there is clearly more work to do to bring more cures to patients,” said Dr. Ross. “Surface Oncology’s strategy targeting the various components of the tumor microenvironment has an excellent chance of achieving that goal. I look forward to working closely with this outstanding team to move their programs to the clinic as rapidly as possible.”

 

Read More

PatientPing Raises $31.6 Million from Andreessen Horowitz and Leerink Transformation Partners to Accelerate Growth of its National Care Coordination Network

PatientPing, a health technology company that connects providers to seamlessly coordinate patient care, announced today that it has received $31.6 million in Series B funding led by Silicon Valley firm Andreessen Horowitz and Boston-based Leerink Transformation Partners (LTP). The funding will help fuel the company’s rapid expansion into new geographies and accelerate the development of product enhancements. PatientPing also plans to at least double the size of its team by actively hiring inspired change-makers for its growth, operations, engineering, and product development teams. This announcement comes just over a year after announcing $9.6 million in seed and series A funding, bringing the total funding amount to $41.2 million, to date.

PatientPing’s flagship product offers real-time notifications (“Pings”) to providers whenever their patients experience an admit, transfer or discharge to or from a facility. The Company has become the country’s leading provider of clinical event notifications, creating the nation’s largest community of providers working together to coordinate patient care. PatientPing’s product is unique in that it spans across the entire continuum of care—acute, ambulatory, and post-acute facilities—regardless of EMR, provider network, or other institutional barriers that have historically created silos between providers. At the facility where patients are getting care, providers also receive care instructions that include contact information for others on the patient’s care team as well as patient visit histories.

 

Read More